Zydus Cadila has expanded its rapidly growing roster of generic approvals in the US with Food and Drug Administration (FDA) clearance for its first transdermal patch, a rivastigmine transdermal system for treating dementia associated with Alzheimer’s and Parkinson’s diseases.
Both US patents listed against the reference brand, Novartis’ Exelon Patch, in the FDA’s Orange Book expired in January this...



